Biofrontera Inc. (BFRI)


+0.65 (+7.60%)
Symbol BFRI
Price $9.2
Beta 0.000
Volume Avg. 0.02M
Market Cap 12.582M
Shares () -
52 Week Range 7.4-25.8
1y Target Est -
DCF Unlevered BFRI DCF ->
DCF Levered BFRI LDCF ->
ROE -128.79% Strong Sell
ROA -61.42% Strong Sell
Operating Margin -
Debt / Equity 30.60% Neutral
P/E -0.50 Neutral
P/B 0 Neutral


Consensus EPS

Upgrades & Downgrades

Latest BFRI news

Dr. Hermann Luebbert Ph.D.
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.